Search Results - "McArthur, G.A."

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA by Tan, L., Sandhu, S., Lee, R.J., Li, J., Callahan, J., Ftouni, S., Dhomen, N., Middlehurst, P., Wallace, A., Raleigh, J., Hatzimihalis, A., Henderson, M.A., Shackleton, M., Haydon, A., Mar, V., Gyorki, D.E., Oudit, D., Dawson, M.A., Hicks, R.J., Lorigan, P., McArthur, G.A., Marais, R., Wong, S.Q., Dawson, S.-J.

“…The advent of effective adjuvant therapies for patients with resected melanoma has highlighted the need to stratify patients based on risk of relapse given the…”
Get full text

A Phase 1, Open-Label, Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of a first in class Pol1 inhibitor (CX-5461) in Patients with Advanced Haematologic Malignancies (HM) by Khot, A, Brajanovski, N, Cameron, D, Hein, N, McArthur, G.A, Lim, J.K.C, O'Brien, S.E, Ryckman, D, Yu, G.I, Link, E, Donohoe, C, Snowden, A, Hannan, R, Harrison, S.J

Get full text

30 (PB018): Improved BRAF/MEK inhibitor efficacy in melanoma using a high-fat diet in male mice by Arabi, S., Saleh, R., Schenk, D., McArthur, G.A., Sheppard, K.E.

Get full text

87 BEZ235, a dual PI3K/mTORC inhibitor, targets the DNA damage response leading to radiosensitization and senescence by Azad, A, Natoli, A, Jackson, S, Maira, S.M, Hackl, W, Cullinane, C, McArthur, G.A, Solomon, B

Get full text

633 The contribution of dysregulated ribosomal gene transcription to malignant transformation by Hannan, R.D, Bywater, M.J, Poortinga, G, Cullinane, C, Stanley, K, Walker, R, Drygin, D, Anderes, K, Pearson, R, McArthur, G.A

Get full text

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study by McArthur, G.A., Maio, M., Arance, A., Nathan, P., Blank, C., Avril, M.-F., Garbe, C., Hauschild, A., Schadendorf, D., Hamid, O., Fluck, M., Thebeau, M., Schachter, J., Kefford, R., Chamberlain, M., Makrutzki, M., Robson, S., Gonzalez, R., Margolin, K.

“…Vemurafenib has shown activity in patients withBRAFV600 mutated melanoma with brain metastases (BM). This phase 2 study evaluated vemurafenib in patients…”
Get full text

Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study by Dréno, B., Ribas, A., Larkin, J., Ascierto, P.A., Hauschild, A., Thomas, L., Grob, J.-J., Koralek, D.O., Rooney, I., Hsu, J.J., McKenna, E.F., McArthur, G.A.

“…In the coBRIM phase III trial, the addition of cobimetinib, an MEK inhibitor, to vemurafenib, a BRAF inhibitor, significantly improved progression-free…”
Get full text

Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells by Ferrao, P T, Bukczynska, E P, Johnstone, R W, McArthur, G A

“…CHK1 and CHK2 function as effectors of cell cycle checkpoint arrest following DNA damage. Small molecule inhibitors of CHK proteins are under clinical…”
Get full text

1379TiP - A phase II, open-label, randomized, multicenter trial of encorafenib + binimetinib evaluating a standard-dose and a high-dose regimen in patients with BRAFV600-mutant melanoma brain metastasis (MBM) (POLARIS) by Davies, M.A., Weber, J.S., Flaherty, K.T., McArthur, G.A., Reddy, M.B., Golden, A., Culbertson, J.L., Thomas, C.T., Tawbi, H.A., Long, G.V.

“…Melanoma that metastasizes to the brain has a poor prognosis, and accounts for up to 54% of melanoma deaths. Clinical data show that treatment with…”
Get full text

A phase II, open-label, randomized, multicenter trial of encorafenib + binimetinib evaluating a standard-dose and a high-dose regimen in patients with BRAFV600-mutant melanoma brain metastasis (MBM) (POLARIS) by Davies, M.A., Weber, J.S., Flaherty, K.T., McArthur, G.A., Reddy, M.B., Golden, A., Culbertson, J.L., Thomas, C.T., Tawbi, H.A., Long, G.V.

Get full text

Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation–positive melanoma by Robert, C., Lewis, K.D., Gutzmer, R., Stroyakovskiy, D., Gogas, H., Protsenko, S., Pereira, R.P., Eigentler, T., Rutkowski, P., Demidov, L., Caro, I., Forbes, H., Shah, K., Yan, Y., Li, H., McArthur, G.A., Ascierto, P.A.

“…The phase III IMspire150 study (NCT02908672) demonstrated significantly improved progression-free survival (PFS) with atezolizumab, vemurafenib, and…”
Get full text

Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma by Middleton, M.R., Friedlander, P., Hamid, O., Daud, A., Plummer, R., Falotico, N., Chyla, B., Jiang, F., McKeegan, E., Mostafa, N.M., Zhu, M., Qian, J., McKee, M., Luo, Y., Giranda, V.L., McArthur, G.A.

“…Veliparib (ABT-888) is a potent, orally bioavailable, small-molecule inhibitor of the DNA repair enzymes poly ADP-ribose polymerase-1 and -2. Veliparib…”
Get full text

Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma by Lewin, J., Sayers, L., Kee, D., Walpole, I., Sanelli, A., te Marvelde, L., Herschtal, A., Spillane, J., Gyorki, D., Speakman, D., Estall, V., Donahoe, S., Pohl, M., Pope, K., Chua, M., Sandhu, S., McArthur, G.A., McCormack, C.J., Henderson, M., Hicks, R.J., Shackleton, M.

“…As early detection of recurrent melanoma maximizes treatment options, patients usually undergo post-operative imaging surveillance, increasingly with…”
Get full text

1311O - Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC) by Long, G.V., Atkinson, V.G., Lo, S., Sandhu, S.K., Brown, M., Gonzalez, M., Guminski, A., Scolyer, R.A., Emmett, L., Menzies, A.M., McArthur, G.A.

“…Preliminary data from the ABC (76 pts, med f/u 17mo) and CheckMate 204 (94 pts, med f/u 14mo) trials showed that nivo and nivo+ipi have activity in active…”
Get full text

Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC) by Long, G.V., Atkinson, V.G., Lo, S., Sandhu, S.K., Brown, M., Gonzalez, M., Guminski, A., Scolyer, R.A., Emmett, L., Menzies, A.M., McArthur, G.A.

Get full text

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib by Reichardt, P., Blay, J.-Y., Gelderblom, H., Schlemmer, M., Demetri, G.D., Bui-Nguyen, B., McArthur, G.A., Yazji, S., Hsu, Y., Galetic, I., Rutkowski, P.

“…This phase III open-label trial investigated the efficacy of nilotinib in patients with advanced gastrointestinal stromal tumors following prior imatinib and…”
Get full text

The role of BRAF mutations in primary melanoma growth rate and survival by Mar, V.J., Liu, W., Devitt, B., Wong, S.Q., Dobrovic, A., McArthur, G.A., Wolfe, R., Kelly, J.W.

“…Summary Background The clinical behaviour and prognosis of primary melanomas harbouring BRAF mutations is not fully understood. Objectives To investigate the…”
Get full text

Impact of duration of response (DOR) on overall survival (OS) in patients with metastatic melanoma treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib plus vemurafenib (C+V): a pooled analysis by Lewis, K., Larkin, J., Ribas, A., Flaherty, K.T., McArthur, G.A., Ascierto, P.A., Dréno, B., McKenna, E., Zhu, Q., Mun, Y., Hauschild, A.

Get full text

Prognostic impact of early complete metabolic response on FDG-PET, in BRAF V600 mutant metastatic melanoma patients treated with combination vemurafenib & cobimetinib by Xu, W., Frederickson, J., Callahan, J., Ribas, A., Gonzalez, R., Pavlick, A.C., Hamid, O., Gajewski, T., Puzanov, I., Daud, A., Colburn, D., Choong, N., Wongchenko, M., Hicks, R., McArthur, G.A.

Get full text

Sensitive detection of TERT promoter mutations reveals early acquisition and heterogeneity in cutaneous melanoma by Colebatch, A.J., Witkowski, T., Waring, P.M., McArthur, G.A., Wong, S.Q., Dobrovic, A.

Get full text